Synairgen

0:04:37

Synairgen CEO lays out plans for 2023 and beyond

0:03:05

Synairgen Seeks FDA, EMA Engagement on Covid-19 Drug

0:00:24

Synairgen on backing for pivotal clinical trial

0:03:17

Synairgen provides update on progress during 2023

0:30:34

Richard Marsden, CEO - Synairgen (SNG) at SHARES Investor Evenings

0:05:27

Synairgen says its drug well tolerated in phase II trial

0:03:55

Synairgen looking beyond COVID in fight against respiratory illness

0:03:07

Synairgen CEO on funding critical Phase 2 trial for SNG001

0:05:51

Synairgen PLC pleased with further positive data from lead COPD drug

0:08:29

Synairgen’s Covid treatment can still have a role in severe cases explains CEO Marsden

0:01:23

Ariana Resources, Gem Resources, Cordiant Digital, 4GLOBAL, Synairgen - Small Cap Snapshot

0:07:15

Synairgen PLC's Richard Marsden hails positive results from study on COVID-19 patients

0:19:36

Synairgen awaits Covid-19 treatment clinical test results in July

0:09:10

BIO-Europe® 2018: Synairgen developing COPD treatment to hold off further viral damage

0:11:29

In Conversation with Richard Marsden, CEO, Synairgen

0:12:47

Synairgen: Richard Marsden presents updates on all three Covid-19 treatment trials

0:01:25

Synairgen — Antivirals

0:06:59

Synairgen PLC on presenting at the ATS conference in San Francisco

0:02:04

Synairgen announce positive results from trial of SNG001

0:04:08

Coronavirus: Protein treatment trial 'a breakthrough' - BBC News

0:00:36

British firm presents treatment trial slashing COVID-19 death risk | AFP

0:05:28

Synairgen’s CEO Richard Marsden details the company’s plans following 2022 interim results

0:04:26

Synairgen chief delighted with amended fibrosis collaboration deal

0:03:09

Coronavirus: experimental drug stops virus from progressing